The Molecule at the Center of Aging
Every cell in your body runs on a molecule you have probably never heard of. It is called nicotinamide adenine dinucleotide, or NAD+, and it is involved in hundreds of essential biological processes — from converting food into energy to repairing damaged DNA. Without NAD+, you would be dead in about 30 seconds.
Here is the problem: NAD+ levels decline dramatically as you age. By the time you are 50, you may have roughly half the NAD+ you had at 20. By 80, you might have only a quarter. This decline has been linked to virtually every hallmark of aging — mitochondrial dysfunction, genomic instability, epigenetic alterations, cellular senescence, and chronic inflammation.
This observation has sparked one of the most talked-about ideas in longevity science: what if you could simply refill the tank? What if boosting NAD+ levels could slow, halt, or even reverse aspects of aging?
That question has launched a billion-dollar supplement industry, ignited heated scientific debate, and turned Harvard geneticist David Sinclair into the most visible advocate for NAD+ supplementation. But the gap between the hype and the hard evidence is worth understanding before you reach for your credit card.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, essential for energy metabolism and DNA repair. Image: Wikimedia Commons / Public Domain.
What NAD+ Actually Does
NAD+ is a coenzyme — a helper molecule that enzymes need in order to work. It participates in two broad categories of cellular activity that are critical to understanding why it matters for aging.
Energy metabolism. NAD+ is essential for cellular respiration, the process by which mitochondria convert nutrients into ATP — the energy currency of the cell. NAD+ shuttles electrons in a chemical relay race through glycolysis, the citric acid cycle, and the electron transport chain. Without adequate NAD+, mitochondria cannot produce energy efficiently, and mitochondrial dysfunction is one of the twelve recognized hallmarks of aging.
DNA repair and gene regulation. NAD+ is the exclusive fuel for a family of enzymes called sirtuins (SIRT1 through SIRT7 in mammals) and another family called PARPs (poly-ADP-ribose polymerases). Sirtuins regulate gene expression, protect against genomic instability, and coordinate the cellular stress response. PARPs detect and repair DNA damage. Both consume NAD+ every time they work — they literally break the molecule apart to do their jobs. As you age and accumulate more DNA damage, PARPs consume more NAD+, potentially starving sirtuins of the fuel they need to keep cells healthy.
There is also CD38, an enzyme that degrades NAD+ and whose activity increases with age and chronic inflammation. Rising CD38 activity is now thought to be one of the major reasons NAD+ levels fall as we get older — perhaps even more significant than declining production.
The net result is a vicious cycle: aging increases NAD+ consumption, lower NAD+ impairs the repair and maintenance systems that protect against aging, and the damage accelerates further.
Why NAD+ Declines With Age
The age-related decline in NAD+ is well documented. A 2019 study published in Cell Metabolism by Camacho-Pereira and colleagues showed that CD38 expression increases in multiple tissues with age in mice, directly driving NAD+ decline. Blocking CD38 with pharmacological inhibitors restored NAD+ levels and improved mitochondrial function.
Several factors contribute to the decline:
- Increased CD38 activity — Chronic, low-grade inflammation (sometimes called "inflammaging") drives up CD38 expression, which chews through NAD+ reserves
- Increased PARP activity — More DNA damage means more PARP activation, consuming more NAD+
- Reduced NAMPT expression — NAMPT is the rate-limiting enzyme in the salvage pathway that recycles NAD+. Its activity decreases with age in some tissues
- Dietary factors — NAD+ is ultimately derived from vitamin B3 (niacin) and related precursors. Poor diet can contribute to lower levels, though this is rarely the primary driver of age-related decline
The critical question is whether low NAD+ is a cause of aging or a consequence — or, as most researchers suspect, both. This distinction matters because it determines whether boosting NAD+ will actually help or merely paper over a deeper problem.
NMN vs. NR: Two Roads to NAD+
You cannot simply swallow a NAD+ pill. The molecule itself is too large and unstable to survive digestion and enter cells efficiently. Instead, researchers have focused on precursors — smaller molecules that cells can absorb and convert into NAD+ internally.
The two leading NAD+ precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are forms of vitamin B3, and both feed into the NAD+ salvage pathway, but they enter the pathway at slightly different points.
The NAD+ salvage pathway: NR is converted to NMN by NRK enzymes, and NMN is then converted to NAD+ by NMNAT enzymes. Both precursors ultimately feed into the same pathway. Image: Wikimedia Commons / CC BY-SA 4.0.
NR (nicotinamide riboside) enters cells directly and is phosphorylated to NMN by NRK (nicotinamide riboside kinase) enzymes inside the cell. NMN is then converted to NAD+ by NMNAT enzymes. NR has been on the market longer, is sold under brand names like Tru Niagen (by ChromaDex), and has more published human clinical data. It was the first NAD+ precursor to receive FDA "Generally Recognized As Safe" (GRAS) status as a dietary ingredient.
NMN (nicotinamide mononucleotide) is one step closer to NAD+ in the biosynthetic pathway. For years, scientists debated whether NMN could even enter cells directly — it was thought to be too large to cross cell membranes. In 2019, a transporter protein called Slc12a8 was identified that appeared to facilitate NMN uptake in the gut, though this finding remains debated. More recent evidence suggests that NMN may also be converted to NR outside the cell, absorbed, and then reconverted to NMN inside — meaning the two precursors may partially converge on the same entry route.
How They Compare
| Feature | NMN | NR |
|---|---|---|
| Steps to NAD+ | 1 (NMN to NAD+) | 2 (NR to NMN to NAD+) |
| Cell entry | Via Slc12a8 transporter (debated) or conversion to NR | Direct entry via equilibrative nucleoside transporters |
| Human clinical data | Growing (10+ published trials) | More extensive (20+ published trials) |
| FDA status | Regulatory limbo (see below) | GRAS-affirmed as dietary ingredient |
| Key brand | ProHealth, Renue By Science, others | Tru Niagen (ChromaDex) |
| Typical dose | 250-1000 mg/day | 300-1000 mg/day |
| Monthly cost | $30-$80 | $30-$50 |
The honest truth is that there is no definitive evidence that one precursor is meaningfully superior to the other for boosting NAD+ levels in humans. Both have been shown to increase blood NAD+ levels. The debate over which is "better" generates far more heat than light.
David Sinclair and the Case for NMN
No single person has done more to popularize NMN than David Sinclair, a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. Sinclair's laboratory has produced many of the foundational studies on NAD+ and aging, and he has been extraordinarily public about his personal use of NMN supplements.
Sinclair has stated publicly that he takes NMN daily as part of his personal longevity regimen. In his 2019 bestselling book Lifespan: Why We Age — and Why We Don't Have To, he wrote: "NAD+ is one of the most important molecules in the body. Without it, we'd be dead in 30 seconds." He has described NAD+ decline as a central mechanism driving the aging process and has argued that replenishing it could be transformative.
In a widely viewed 2021 interview on the Joe Rogan Experience, Sinclair elaborated on his hypothesis: "I think that the loss of NAD is one of the reasons we get old. It's not the only reason, but it's a big one. And what's exciting is that we can do something about it."
The Mouse Data
Sinclair's laboratory has published several influential studies demonstrating the effects of NAD+ boosting in mice:
- A 2013 study in Cell showed that raising NAD+ levels in old mice restored mitochondrial function to youthful levels within just one week of NMN treatment. The aged mice showed improvements in insulin sensitivity, lipid metabolism, and other markers
- A 2018 study published in Cell Reports demonstrated that NMN supplementation improved blood vessel growth and endurance in aged mice, with old mice gaining 50-80% more endurance capacity
- A 2020 study in Science from his lab, working with Yuancheng Lu, showed that epigenetic reprogramming could reverse age-related vision loss in mice — work that intersects with NAD+ biology through sirtuin activation
These mouse studies are genuinely impressive. The improvements in mitochondrial function, vascular health, and exercise capacity were large and reproducible. Sinclair has been careful to note that mouse results do not guarantee human benefits, but he has also been more optimistic than many of his peers about the translational potential.
"Mice are not humans," Sinclair has acknowledged. "But the pathways are conserved. NAD+, sirtuins, DNA repair — these are ancient systems that evolution has maintained across species for hundreds of millions of years."
What Human Clinical Trials Actually Show
The mouse data is encouraging, but what matters for people considering NMN or NR supplements is the human evidence. Here is where the picture becomes more nuanced.
NMN Human Trials
Several Phase I and Phase II clinical trials of NMN have been completed:
The first-in-human NMN safety trial (2020, Irie et al., published in Endocrine Journal) demonstrated that single oral doses of NMN up to 500 mg were safe and well-tolerated in healthy men. NMN was rapidly absorbed and metabolized, with no serious adverse effects. This was a safety study, not designed to show efficacy.
The 2022 Yi et al. trial (published in Science) was a randomized, double-blind, placebo-controlled study of 250 mg NMN daily in overweight or obese postmenopausal women with prediabetes. After 10 weeks, NMN improved skeletal muscle insulin sensitivity by approximately 25%, increased insulin signaling, and enhanced muscle remodeling. This was one of the first rigorous demonstrations of a metabolic benefit of NMN in humans.
A 2022 Yoshino et al. study showed that NMN supplementation increased NAD+ metabolites in blood and improved muscle insulin sensitivity in prediabetic women, consistent with the metabolic benefits seen in mice.
The 2022 Liao et al. trial in healthy middle-aged adults found that NMN supplementation (300-900 mg/day for 60 days) was safe and increased blood NAD+ concentrations in a dose-dependent manner. Some improvements in physical performance metrics were observed, though the study was small.
A 2023 Kim et al. trial examined NMN supplementation (250 mg twice daily) in healthy middle-aged adults and found improvements in walking speed, grip strength, and a reduction in drowsiness and lower limb function, though again in a relatively small sample.
NR Human Trials
NR has a larger body of human clinical data:
The CHRO-NICE trial (Martens et al., 2018, published in Nature Communications) showed that NR supplementation (1000 mg/day for 6 weeks) was well-tolerated in healthy middle-aged and older adults and raised blood NAD+ levels by approximately 60%. However, it did not significantly improve blood pressure, arterial stiffness, or metabolic markers in this short-term study.
A 2019 Dollerup et al. trial in obese men found that NR (2000 mg/day for 12 weeks) did not improve insulin sensitivity, mitochondrial function, or body composition compared to placebo — a disappointing result that tempered enthusiasm.
More recent NR studies have shown benefits in specific populations, including improvements in mitochondrial function in heart failure patients and reduced inflammation in certain contexts, but results have been inconsistent.
The Bottom Line on Human Evidence
The human data tells a clear story: NAD+ precursors are safe and they reliably boost NAD+ levels in blood and tissues. What remains unproven is whether this translates into meaningful clinical benefits for healthy people.
The most robust finding to date is the improvement in muscle insulin sensitivity in prediabetic women — a legitimate metabolic benefit, but a far cry from the dramatic age-reversal seen in mice. No human trial has demonstrated that NMN or NR extends lifespan, reverses biological age, prevents age-related disease, or produces the kind of sweeping rejuvenation effects seen in rodent studies.
This does not mean the supplements do not work. It may simply mean that the right studies — large, long-term, in the right populations — have not been done yet.
The FDA and NMN's Regulatory Limbo
In November 2022, the FDA dropped a bombshell on the NMN supplement market. The agency ruled that NMN could no longer be marketed as a dietary supplement because it was being investigated as a new drug by Metro International Biotech, a company co-founded by David Sinclair. Under FDA rules, once a substance is under investigation as a drug, it generally cannot be sold as a supplement.
This created a regulatory paradox. NMN had been widely available as a supplement for years. Consumers could still find it online and in stores — enforcement was not immediate — but the legal landscape shifted overnight. Some companies reformulated or relabeled products. Others continued selling NMN and challenged the FDA's interpretation.
The Natural Products Association and several NMN manufacturers filed citizen petitions and legal challenges. As of early 2026, the situation remains unresolved, with NMN occupying a gray area — technically not FDA-approved as a supplement, but widely available for purchase. NR, by contrast, has maintained its GRAS status and faces no such regulatory complications.
This regulatory uncertainty has understandably confused consumers. It is worth emphasizing that the FDA's action was about regulatory classification, not safety. The agency did not declare NMN unsafe — it said NMN could not be sold as a supplement while under drug investigation. This is a procedural distinction, but it has real consequences for product availability and consumer confidence.
What the Critics Say
Not all longevity researchers share Sinclair's enthusiasm for NAD+ supplementation. The criticism falls into several categories:
The mouse-to-human translation problem. Charles Brenner, the biochemist who discovered NR's role as an NAD+ precursor, has been vocal about the need for rigorous human data before making sweeping claims. He has cautioned that mouse studies, while informative, often fail to translate to humans — a pattern seen across all of biomedical research, not just aging.
Questioning the mechanism. Some researchers argue that even if NAD+ levels are successfully boosted, the downstream effects may be limited by other bottlenecks in the aging process. If the problem is not just low NAD+ but damaged mitochondria, accumulated senescent cells, or dysfunctional proteostasis, then raising NAD+ levels alone may be insufficient.
The bioavailability debate. Eric Verdin, president of the Buck Institute for Research on Aging, has noted that oral supplements face significant bioavailability challenges. Much of an oral NMN or NR dose may be metabolized in the liver before reaching target tissues. Whether enough active precursor reaches the cells that need it most — brain, heart, muscle — remains an open question.
The lack of lifespan data. Perhaps the most significant criticism: no human study has shown that NAD+ supplementation extends lifespan. The mouse lifespan data is itself mixed — some studies show modest lifespan extension with NMN, while others do not. Without clear lifespan data even in mice, the human longevity claims are speculative.
Sinclair has responded to these critiques by emphasizing that the field is young, that the early human data is consistent with the animal findings, and that waiting for decades-long lifespan studies before acting would be impractical. "We don't have the luxury of waiting 40 years for a perfect clinical trial," he has said. "The biology is compelling, and the safety data is strong."
How NAD+ Compares to Other Longevity Interventions
NAD+ supplementation does not exist in a vacuum. It competes for attention — and money — with several other longevity interventions that have their own evidence bases.
Exercise remains the single most evidence-backed longevity intervention. Regular physical activity improves cardiovascular health, insulin sensitivity, mitochondrial function, cognitive performance, and reduces all-cause mortality by 25-35% in large epidemiological studies. Notably, exercise also raises NAD+ levels naturally by activating NAMPT and AMPK. No supplement has come close to matching the breadth and depth of evidence supporting exercise.
Caloric restriction extends lifespan in yeast, worms, flies, and mice. In the landmark CALERIE trial in humans, modest caloric restriction (12% below normal) for two years improved cardiometabolic markers, reduced oxidative stress, and slowed some measures of biological aging. Caloric restriction also boosts NAD+ levels through sirtuin and AMPK activation — raising the question of whether NMN supplements are simply trying to mimic what diet and fasting do naturally.
Rapamycin (an mTOR inhibitor) is the only drug that has consistently extended lifespan in mice, including when started in old age. It works through a different mechanism than NAD+ — suppressing growth signaling rather than boosting repair — and has known side effects including immunosuppression. Rapamycin is increasingly used off-label by longevity enthusiasts, but human lifespan data does not exist.
Senolytics — drugs that clear senescent cells — represent another promising strategy. The combination of dasatinib and quercetin has shown benefits in mouse studies and early human trials, targeting a different hallmark of aging entirely.
Metformin, the diabetes drug, is the subject of the landmark TAME (Targeting Aging with Metformin) trial, which aims to determine whether it can delay age-related diseases as a class. Metformin is cheap, well-understood, and has decades of human safety data, though its longevity benefits beyond glucose control remain unproven.
The most honest assessment is that NAD+ supplementation is one piece of a complex puzzle. It addresses one hallmark of aging (mitochondrial dysfunction and deregulated nutrient sensing) but does not directly target others (telomere attrition, cellular senescence, loss of proteostasis). A comprehensive longevity strategy would likely involve multiple interventions — and exercise should be at the top of anyone's list regardless of what supplements they take.
Consumer Products: What Is Available
For consumers who want to try NAD+ precursors despite the incomplete evidence, here is the current landscape:
NMN Products
- ProHealth Longevity NMN Pro — 500 mg capsules, third-party tested; approximately $50-70/month at typical doses
- Renue By Science — Offers sublingual NMN lozenges (designed for absorption under the tongue to bypass liver metabolism), liposomal formulations, and standard capsules; $40-80/month
- Alive By Science — Similar range of NMN delivery formats
- DoNotAge — UK-based; offers high-purity NMN powder and capsules
NR Products
- Tru Niagen (ChromaDex) — The market leader for NR; 300 mg capsules, FDA GRAS-affirmed, backed by the largest body of published clinical data; approximately $40-50/month
- Life Extension NAD+ Cell Regenerator — Contains NR (as Niagen); $20-35/month
What to Look For
- Third-party testing certificates — Independent verification of purity and potency (look for COA from labs like NSF, USP, or independent testing)
- Dosage alignment with clinical data — Most positive NMN trials used 250-500 mg/day; most NR trials used 300-1000 mg/day
- Reputable manufacturer — Look for companies with published research or transparent sourcing
- Realistic claims — Any product claiming to "reverse aging" or "extend lifespan" is making claims that the evidence does not yet support
It is also worth noting the cost. At $40-80 per month indefinitely, NAD+ supplementation is a significant financial commitment — especially for an intervention whose long-term benefits remain unproven. For many people, that money might be better spent on a gym membership, higher-quality food, or better sleep.
An Honest Bottom Line
NAD+ is genuinely important. Its decline with age is real, well-documented, and mechanistically linked to multiple aspects of aging. The mouse data showing benefits from NMN and NR supplementation is compelling and has been replicated across multiple laboratories. David Sinclair and other researchers have built a credible scientific case that NAD+ depletion contributes to age-related decline.
But the human evidence is still early-stage. The supplements are safe, they raise NAD+ levels, and there are hints of metabolic benefits in specific populations. That is promising. What has not been demonstrated in any human trial is lifespan extension, disease prevention, or the kind of comprehensive rejuvenation that would justify the most optimistic claims circulating online and in supplement marketing.
The responsible position is this: NAD+ precursors are among the more scientifically interesting supplement options available, backed by real biology and genuine clinical trials. They are not miracle pills. If you choose to try them, do so with realistic expectations, choose products that have been third-party tested, and do not let supplementation substitute for the interventions that are already proven — exercise, healthy diet, adequate sleep, stress management, and preventive medical care.
The NAD+ story is far from over. Larger and longer human trials are underway. The regulatory situation will eventually be resolved. And the fundamental biology of NAD+, sirtuins, and cellular energy metabolism will continue to be studied regardless of what happens in the supplement market.
As Sinclair himself has noted: "We're at the beginning of understanding how to treat aging as a medical condition. NAD+ is part of that story, but it's not the whole story."
For now, that nuance is the most honest thing anyone can tell you.
Sources and Further Reading
- Imai, S. & Guarente, L. "NAD+ and sirtuins in aging and disease." Trends in Cell Biology 24, 464-471 (2014). https://doi.org/10.1016/j.tcb.2014.04.002
- Camacho-Pereira, J. et al. "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism." Cell Metabolism 23, 1127-1139 (2016). https://doi.org/10.1016/j.cmet.2016.05.006
- Gomes, A.P. et al. "Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging." Cell 155, 1624-1638 (2013). https://doi.org/10.1016/j.cell.2013.11.037
- Das, A. et al. "Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging." Cell 173, 74-89 (2018). https://doi.org/10.1016/j.cell.2018.02.008
- Yoshino, M. et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science 372, 1224-1229 (2021). https://doi.org/10.1126/science.abe9985
- Irie, J. et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal 67, 153-160 (2020). https://doi.org/10.1507/endocrj.EJ19-0313
- Martens, C.R. et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications 9, 1286 (2018). https://doi.org/10.1038/s41467-018-03421-7
- Dollerup, O.L. et al. "A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects." American Journal of Clinical Nutrition 108, 343-353 (2018). https://doi.org/10.1093/ajcn/nqy132
- Sinclair, D.A. Lifespan: Why We Age — and Why We Don't Have To. Atria Books (2019). https://lifespanbook.com
- Covarrubias, A.J. et al. "NAD+ metabolism and its roles in cellular processes during ageing." Nature Reviews Molecular Cell Biology 22, 119-141 (2021). https://doi.org/10.1038/s41580-020-00313-x
- FDA. "NMN and Dietary Supplement Exclusion Provision." Response letter to Natural Products Association (2022). https://www.fda.gov
- Kim, M. et al. "Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults." Nutrients 14, 755 (2022). https://doi.org/10.3390/nu14040755
Last updated: February 2026.
